Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Hybridoma Technology01:31

Hybridoma Technology

17.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.2K
Affinity and Avidity01:41

Affinity and Avidity

38.4K
Overview
38.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Dual-targeting LILRB3/LILRB4 CAR-T cells for the treatment of monocytic acute myeloid leukemia.

Biochemical pharmacology·2026
Same author

Structure-guided design of potent tetrazolo[1,5-a]pyrimidine-based tubulin inhibitors with in vivo antitumor activity.

European journal of medicinal chemistry·2025
Same author

Discovery of Novel 4,5-Dihydropyrrolo[3,4-<i>c</i>]pyrazol-6(<i>2H</i>)-one-Based Tubulin Inhibitors Targeting Colchicine Binding Site with Potent Anti-Ovarian Cancer Activity.

Journal of medicinal chemistry·2025
Same author

Antibody-drug conjugates targeting DDR1 as a novel strategy for treatment of breast cancer.

Journal of drug targeting·2024
Same author

Discovery and mechanistic insights into thieno[3,2-d]pyrimidine and heterocyclic fused pyrimidines inhibitors targeting tubulin for cancer therapy.

European journal of medicinal chemistry·2024
Same author

Emerging trends in small molecule inhibitors targeting aldosterone synthase: A new paradigm in cardiovascular disease treatment.

European journal of medicinal chemistry·2024

相关实验视频

Updated: Jan 11, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.1K

人工智能在抗体-药物联合开发中的作用

Yuxi Wang1, Cuiyu Guo2, Weimin Li1

  • 1Department of Pulmonary and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China; Frontiers Medical Center, Tianfu Jincheng Laboratory, Chengdu, 610212, Sichuan, China.

Trends in pharmacological sciences
|November 11, 2025
PubMed
概括

人工智能 (AI) 正在通过启用数据驱动工程来彻底改变抗体-药物联合体 (ADC) 开发. 人工智能加速ADC的设计和优化,以实现更有效的癌症治疗.

关键词:
抗体 药物联合体 抗体 药物联合体人工智能的人工智能是人工智能.发现药物的发现.机器学习是机器学习.

更多相关视频

Efficient and Site-specific Antibody Labeling by Strain-promoted Azide-alkyne Cycloaddition
09:06

Efficient and Site-specific Antibody Labeling by Strain-promoted Azide-alkyne Cycloaddition

Published on: December 23, 2016

22.1K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.3K

相关实验视频

Last Updated: Jan 11, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.1K
Efficient and Site-specific Antibody Labeling by Strain-promoted Azide-alkyne Cycloaddition
09:06

Efficient and Site-specific Antibody Labeling by Strain-promoted Azide-alkyne Cycloaddition

Published on: December 23, 2016

22.1K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.3K

科学领域:

  • 在瘤学瘤学.
  • 生物技术是生物技术.
  • 计算生物学 计算生物学

背景情况:

  • 抗体-药物合物 (ADC) 是针对癌症治疗的先进疗法.
  • ADC开发面临的挑战包括设计复杂性,毒性和可变的临床疗效.
  • 优化ADC需要精确匹配抗体,链接器和有效载荷,以获得稳定性和瘤特异性释放.

研究的目的:

  • 审查人工智能 (AI) 在推动抗体-药物联合体 (ADC) 开发中的应用.
  • 要突出AI如何整合各种数据以改善ADC设计和临床翻译.
  • 概述人工智能驱动下一代ADC的未来机会.

主要方法:

  • 人工智能模型整合了抗体序列,结构和分子动力学 (MD) 特性.
  • 数据驱动的方法正在将ADC开发从经验方法转向闭环工程.
  • 综述综合了临床前和临床ADC开发阶段的进展.

主要成果:

  • 人工智能加速ADC开发的关键方面,包括目标选择和并联优化.
  • 人工智能模型增强了对ADC治疗患者反应的预测.
  • 人工智能为ADC设计提供了更合理,更有效的方法.

结论:

  • 人工智能正在将ADC开发转变为数据驱动,高效的过程.
  • 人工智能集成有望克服ADC设计和临床应用当前的局限性.
  • 人工智能支持的策略对于下一代抗体药物合物的未来至关重要.